US psychiatrists prescribe Wegovy to battle medication-induced weight
gain
Send a link to a friend
[August 03, 2023]
By Elissa Welle
NEW YORK (Reuters) - U.S. psychiatrists are increasingly prescribing the
popular weight-loss drug Wegovy to patients who gain weight from
medicines used to treat mental disorders, such as schizophrenia or
bipolar disorder, according to Reuters interviews with ten prescribers
across the country. Many antipsychotic drugs and mood stabilizers can
cause patients to gain significant weight and contribute to diabetes and
heart disease, the leading cause of death among adults with
schizophrenia.
Complicated by other factors such as inadequate access to healthy food
and lower physical activity, over half of patients with bipolar
depression and schizophrenia are overweight or obese. Novo Nordisk's
Wegovy is self-injected once a week and has been shown to help patients
lose around 15% of their body weight, making it the most effective
treatment available. "It's been a real welcome addition …. for people
who truly have endured significant weight gain because of atypical
antipsychotics and have doggedly tried their best to overcome that,"
said Dr. Joseph Goldberg, a professor of psychiatry at Icahn School of
Medicine at Mount Sinai in New York. Wegovy received U.S. approval as an
obesity treatment in June 2021, while Mounjaro, a similar drug from Eli
Lilly, is expected to be authorized this year. New rivals are also in
development.
The global market for weight-loss drugs is forecast to reach as much as
$100 billion within the decade. Yet the best use of such drugs among
patients with psychiatric diagnoses is just beginning to be understood.
Beyond severe mental health disorders, other patients struggling with
obesity tend to suffer from mental health issues like depression and
anxiety at higher levels than the general population, studies show.
Clinical trials for Wegovy, which belongs to a class of drugs known as
GLP-1 agonists that began as diabetes medicines, excluded psychiatric
patients, a common practice in drug development.
The U.S. Food and Drug Administration has cautioned doctors to monitor
patients taking the drug for development of depression or suicidal
thoughts. Regulators in Europe are now investigating several reports of
patients who experienced suicidal thoughts after starting Wegovy. Novo
did not comment on Wegovy use among psychiatric patients, but its safety
data has not shown a link between the drug and suicidal thoughts.
The Danish drugmaker is "continuously performing surveillance of the
data from ongoing clinical trials and real-world use of its products,"
said spokesperson Natalia Salomao in an email.
LOST WEIGHT, GAINED SELF-CONFIDENCE
Psychiatrists interviewed by Reuters said they are already vigilant
about suicide risk in their patients, and have experience in closely
monitoring for signs of distress whenever they add a new medication. Dr.
Dost Ongur, chief of the psychotic disorders division of Mass General
Brigham McLean Hospital near Boston said use of GLP-1 medications for
psychiatry patients has grown so much that he is considering drafting a
standard approach paper for his staff on prescribing them.
[to top of second column]
|
A selection of injector pens for the
Wegovy weight loss drug are shown in this photo illustration in
Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File
Photo
However, psychiatrists specializing
in eating disorders are wary that drugs like Wegovy could exacerbate
their patients’ focus on weight loss because they are so effective.
A good candidate for Wegovy would be a patient who is capable of
self-administering the medicine, or be supervised in doing so, and
is eager to adopt a healthy lifestyle, said Dr. K. N. Roy Chengappa,
a psychiatrist at University of Pittsburgh Medical Center. New
Yorker Alexander Roger, 23, was diagnosed with bipolar disorder at
age 10. In February, the Fordham University student began taking
Wegovy, prescribed through a collaboration between his
endocrinologist and psychiatrist, to combat the persistent weight
gain from lithium and other mood stabilizers. "When you're on the
psychiatric meds, you're so hungry, you just eat whatever is
available," Roger said. In the last six months, Roger said he lost
30 pounds (13.6 kg) and gained self-confidence and energy. But he is
finding it difficult getting Wegovy from his pharmacy, an experience
common to patients across the country as Novo Nordisk struggles to
meet soaring demand. Some psychiatrists said their prescriptions had
been rejected by patients' health insurance. In such cases, these
doctors said they will refer patients to an endocrinologist, a
specialty recognized for managing diabetes and obesity.
More broadly, health plans are adding restrictions to the use of
Wegovy, which is priced at $1,350 per month, and other weight-loss
drugs due to a spike in their related costs. Dr. Michael Weintraub,
an endocrinologist at NYU Langone Health, said ideally psychiatrists
will work with endocrinologists because weight-loss drugs require
careful monitoring not related to mental health issues.
Others say the next step might be to offer these medications well
before a patient gains significant weight from their antipsychotic
drugs. "Waiting until somebody has gained 50 pounds and has
developed diabetes is just not serving the patient," McLean's Ongur
said.
(Reporting by Elissa Welle in New York; Editing by Michele Gershberg
and Bill Berkrot)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |